Access cutting-edge lung cancer treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Sponsor: Gilead Sciences
Check if you qualify for this lung cancer clinical trial in Washington Dc, DC
If you're searching for lung cancer treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.